BioCentury | Jan 11, 2020

Why buysiders say 2020 could be the year of the CNS

A pair of CNS approvals in the final days of 2019 has only added to the growing momentum buysiders were already tracking for 2020 in the once neglected disease area. Positive regulatory signals are converging...
BC Extra | Jan 9, 2020
Financial News

Jan. 8 Financial Quick Takes: Intra-Cellular raises $295M; plus venture rounds for nference, Eyevensys, Transcenta, Airway, Progentec

Intra-Cellular raises $295M  In an offering priced late Tuesday, Intra-Cellular Therapies Inc. (NASDAQ:ITCI) raised $295 million through the sale of 10 million shares at $29.50. The price is a 4% discount to Intra-Cellular’s close at...
BC Extra | Dec 23, 2019
Company News

Caplyta’s unanticipated schizophrenia approval lifts Intra-Cellular shares

Emerging from a cloud of regulatory questions and mixed clinical results, Intra-Cellular has received FDA approval of Caplyta lumateperone for schizophrenia, sending the company’s shares up 193% to $36.51 on Monday. The stock move added...
BC Extra | Sep 10, 2019
Company News

Sept. 10 Company Quick Takes: Lexicon, Sanofi part ways on diabetes drug; plus Mesoblast-Gruenenthal, Mateon-WideTrial, Intra-Cellular

Sanofi to pay Lexicon $260M as Zynquista ends  Sanofi (NASDAQ:SNY) will pay Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) $208 million up front plus $52 million over the next 12 months as part of the companies’ agreement to...
BC Extra | Aug 6, 2019
Company News

Aug. 6 Company Quick Takes: Sales updates from Alnylam, Sage, Regeneron and GW; plus regulatory updates from MorphoSys and more

Alnylam's Onpattro bests consensus  Sales of amyloidosis therapy Onpattro patisiran from Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) reached $38.2 million in 2Q19, the drug's third full quarter on the market. The figure beat analysts' consensus of $32...
BC Extra | Jul 24, 2019
Company News

July 24 Company Quick Takes: Samsung's Humira biosimilar gets FDA approval; plus Intra-Cellular, Sage and more

FDA approves Samsung's Humira biosimilar  Samsung Bioepis Co. Ltd. (Incheon, South Korea) said FDA approved Hadlima adalimumab-bwwd, a biosimilar of autoimmune drug Humira from AbbVie Inc. (NYSE:ABBV). Samsung's partner Merck & Co. Inc. (NYSE:MRK) will...
BC Extra | Jul 24, 2019
Company News

July 23 Company Quick Takes: FDA approves Pfizer’s Rituxan biosimilar; plus Intra-Cellular, OTC Tamiflu, Cimzia and more

Pfizer’s Rituxan biosimilar approved in U.S.  FDA approved Ruxience rituximab-pvvr from Pfizer Inc. (NYSE:PFE) for non-Hodgkin lymphoma, chronic lymphocytic leukemia and granulomatosis with polyangitis and microscopic polyangitis. Ruxience is the second biosimilar of Rituxan, an...
BC Extra | Jul 8, 2019
Clinical News

Intra-Cellular optimistic on lumateperone's future in bipolar despite mixed Phase III results

While one of its trials missed the primary endpoint, Intra-Cellular is hopeful that the robust treatment response seen in the other Phase III lumateperone trial along with a lack of tolerable treatment options for bipolar...
BioCentury | Jun 29, 2019

All eyes on new modality launches, cancer and rare disease data in 3Q19

While the typical summer lull means fewer catalysts in the third quarter, investors will be keeping a close eye on launches of new modality drugs. Of special interest to multiple buysiders is the launch of...
BC Extra | Jun 15, 2019
Company News

June 13 Company Quick Takes: ISS rebuffs Takeda’s Weber; plus Sage, Blueprint, Tetraphase, Celgene and more

ISS weighs in on Weber  Institutional Shareholder Services recommended Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) shareholders oppose President and CEO Christophe Weber at the June 27 shareholder meeting because “top management is responsible for the...
Items per page:
1 - 10 of 64